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Sotalol is unique among beta-adrenergic blocking drugs in 
possessing significant class III antiarrhythmic actions. The 
present study was designed to assess the relative concentra- 
tion dependence of beta-blocking and class III actions of 
sotalol and to relate the findings to concentrations achieved 
during oral sotalol therapy in humans. Measurements were 
made in anesthetized dogs under control conditions, and 
then in the presence of a series of stable sotalol plasma 
concentrations produced by sequential loading and mainte- 
nance infusions. 
Beta-blocking effects of sotalol, determined by attenua- 
tion of the chronotropic actions of isoproterenol, were seen 
at the lowest dose used. Increases in atria1 and ventricular 
refractory periods (observed in dogs with autonomic block- 
Sotalol is a beta-adrenergic blocking agent that also directly 
increases action potential duration (1,2). This action makes it 
unique among beta-blocking drugs and results in potentially 
important antiarrhythmic properties (3). In fact, sotalol was 
the first class III antiarrhythmic agent to be so classified (1). 
Initial in vitro studies indicated that the beta-blocking dose 
of sotalol is much less than the dose required to alter 
repolarization (2). Wang et al. (4) showed that the sotalol 
dose that produced 50% of maximal beta-blockade (320 mgl 
day) was much lower than the dose (960 mg/day) at which 
significant prolongation of the corrected QT interval (QT,) 
occurred in all patients. This observation suggests that doses 
much higher than the beta-blocking doses of sotalol are 
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ade to exclude beta-receptor-mediated or reflex autonomic 
effects) required much larger doses of sotalol. Half-maximal 
beta-blocking effects occurred at an average sotaiol concen- 
tration of 0.8 f 0.3 mg/liter, an order of magnitude lower 
than the concentrations required for half-maximal effects on 
atrial (6.9 + 1.2 mg/liter, p < 0.01) and ventricular 
(6.8 f 2.8 mg/liter, p < 0.05) refractoriness. 
These results show that substantially higher concentra- 
tions are needed for the class III effects of sotalol than for its 
beta-blocking action. These pharmacodynamic differences 
need to be considered in evaluating the antiarrhythmic 
efficacy and mechanisms of this unusual drug. 
(J Am Co11 Cardioll989:13:1190-4) 
necessary for type III electrophysiologic actions in humans. 
The present experiments were designed to compare the 
concentration-response relations for the beta-blocking and 
for the pure class III effects of sotalol in dogs. 
Methods 
Experimental preparation. A total of 12 mongrel dogs 
were anesthetized with morphine (2 mg/kg subcutaneously) 
and alpha-chloralose (100 mglkg intravenously). They were 
ventilated mechanically by means of an endotracheal tube at 
a rate of 15 respirations/min and with a tidal volume obtained 
from a nomogram. Arterial blood gases were measured, and 
ventilation adjusted to maintain a partial pressure of oxygen 
(PoJ X30 torr and a pH of 7.38 to 7.45. Catheters were 
inserted into a femoral artery and both femoral veins. Two 
electrocardiographic (ECG) leads and arterial blood pressure 
we_-: monitored continuously with the use of a Grass poly- 
graph recorder. 
Sotalol dosage. The effects of five dose levels of sotalol 
were determined in the 12 dogs. Loading and maintenance 
doses of sotalol were calculated to produce a series of steady 
state plasma concentrations (Table 1). All loading doses 
01989 by the American College of Cardiology 0735-1097/89/%3.50 
[ELlJalU! 103 U!Ul L’L pile lO\t?lOS -‘OJ U!UJ 8.f SBM XU!l UO!j 
-uaw aq~ ..~o~alap lalo!Ae4ln q@uaptem alqe!.n2” sJaleM 
c 30 asn aqi ql!M papJosal st2~ UIU gcz it! aw2qJosqe lalo!h 
-e.uln 30 ulawd Bu!ynsa~ aql pue (‘03 sawa!3g ICqdw8olw 
-0-1q3) umnlo:, sao rl 5 e owe papa& aJaM saldmeg ‘p!~‘a 
y.io31nsauel30 -lai@ 6.1 u! payoss!p alyyola3e ohs’cf 
pur! ([“()&)I] ~!sEqouow ‘aleqdsoqd runyelod .tal#? 
go’p) .Iagnq y&99 JO pals!suo3 aseqd apqotu aqJ ‘W.I o@)‘f 
le uy s “03 pa%n3yuar, pur! pale@ uaql pue aseqd apqow 
30 Irl ooz qI!M palnlysuo2aJ uaql SBM uoyqos ayJ w&? 
Ua8O.Il!U %0()1 Japun SSaUhp 01 palE.IOdEAa pue saqnl de:, 
MaIDs alqwodsrp u! paseld SBM label lualzlos Jaddn aql wdJ 
o&f lr! uy 01 103 pa%n3yua3 uaql pue pals@ SEM uoyqos 
aql put? ‘pappc set alela3e lLqla30 sJalggI!w Jnod .aqnl lsal 
alqcsods!p e u! alvqdsoqd turupos 30 %m 0s pue (1818 1~) 
plepuels pX.Ialu! 30 ]‘l Of 01 pappI? SI?M cruseld 30 Jalq!#w 
au0 *I(qdw%olwoJq:, p!nby acwtulopad q%q aseqd-auaA 
-al 30 asn aql ql!M paJnseaw aJaM suogwlua~uo~ eurseld 
lop~jos wogequamo~ aweld lop~os JO yuamamseam 
*apcyDoiq yuouolne payelsns paanpoJd uam!%aJ 
s!ql leql paMoqs sa!pnls iopd *moq qDea sasop %y@u g.0 /cq 
paMoIl ‘lipnouanwlu! loloualr! 30 By@u ~‘0 %ya~sy!wpe 
iiq pawpold SBM apEyDo]q-ela$g *q@u 5’0 hq paMollo3 
@nOUaAWlU! au!dogE 30 %I 130 uoy?.~~s!u$upe aql pur! @A 
p+.Ia:, aql 30 uo!s!~!p 1k?3!%ns Aq palualzald aJaM spaga 
pZZ?e~ .apeyDolq yuouolne qI!M s%op x!s aql u! paw103 
-Jad alaM sluampadxa popad holw3al ilt! ‘au01 3.~0~ 
-olna u! sa8uay~ JuanbasuoJ .IO apvysolq-vlaq Jo luapuad 
-apu! ‘~O~VJOS~O suoym 111 ad4 lsa.+p ayl aywraiap OJ 
*uo!sn3u! Iolelos q3Ea %uyp uaqi pue suop!puoD logJo 
.tapun q$iual algAD qDta IE apwu aJaM sluamamsea~ ‘iClaAg 
-3adsal‘gsg a3tyns aql uo xaldtuo3 ~80 t! .IO weJ8oJl3ala 
leyle UB a3npold 01 8uq!1~3 pwalu! Zs1s )sa%uol aql se pauy 
-ap aJaM spo!Jad /ilolDt?gaJ rync+luaA PUB ~+IIE aypaga 
aqL .ploqsaJql luann:, ~!lolse!p a3!Ml me saslnd ahEM-alenbs 
SW p alaM gnwys 11~ put2 ‘snpwys lsal qciea aJo3aq pasn IBM 
ywys 3!saq ~130 U!EJI v y-wyswlxa 30 uogwqddc aIo3aq 
q@ual al”h u! a%uaq:, q3ea lal3e sarqelz 30 uo!lez!yqals 
103 U!UJ 1 8u!~o~pz ‘yl8uaj a@3 ~!svq yma IV anb!uyDal 
snpuuysvnixa ayi yi!ht pa.msvaur SUM pollad LioimiJay 
*sq&.~al 
al3h yeq 30 a%uw Jap!M e 30 uoynp2Aa aql ~03 ~011x2 
01 paqsw SBM apou sny aql ywu~ue atuos UI 5Sop 1p2 u! 
pasn suI 00s 30 ql8ual a13h 3!seq B ql!M %op qcc?a u! sql%ual 
alsh 3!seq 30 a&w I! Jane paywalap aJaM spouad ,hol 
-3eJ3aa .al3!4uaA pug urny2 aql a~ynuyls 01 qDea apowala 
au0 pw weAio4~a~a legs ur! pJoDa1 01 pasn SCM apon2ala 
au0 .alyluaA lq%y put? (sapowala 0~1) a%puadde p+l~ 
Iqt& aql u! pauasu! alaM sapowala laals ssaluys pale03 
-uoyaJ ‘.yod!q pue ‘pawJopad SBM Awolo~e~oql lqflu 
v .apey3olq y,uouolne ql!M s8op x!s 30 sa!Jas alwadas E? u! 
paywalap aJaM spo!lad ho~~w3a.1 .yn+tluar\ put! loye uo 
~0~~10s 30 sl3aga aqL 23uo!leu!ur~alap po+3d tolm.ga~ 
*[op?los 30 
uo!l~ %!y3Olq-t?laq aql30 xapu! aA!lt?l!]Ut?nb e SE pasn uaql 
SBM loualaloldos! 30 IDaBa cydogouoJq3 aql30 uoyenuafe 
luawad aqJ ?iop q3va u! ~o~elos 30 asop qcea ]e aAJn3 
asuodsaJ-asop IouaJaloldos! aql u10.13 lopgos JO a3uasaJd 
aql U! pa]I?lllt?Aa SBM SUO!l!pUO:, 1OJ1UO3 JapUn ‘Sag aql 01 
Ienba asop loualaloldos! ut! /(q pa3npoId asea.y alel peaq 
aqL %f 9.0 T 87 paihaht? suoypuo:, low03 .iapun OSag 
aqL .uo!sn3u! lolclos q3ea 103 put! suog!puoD loquoD Japun 
pale[nyr?:, SBM (Osag) aleJ uoaq ~XU!XIXII 30 ~0s %u!Dnpo.Id 
asop Ioualaloldos! aqL ‘(5) pau!wlalap SBM (Saph any 
-3asuo3 z 30 pwalu! xa ueaw aqj 30 asn aql q1w passassv) 
asuodsal aw waq ysad aql pur! 8ti OZE JO 001 ‘ZE ‘01 ‘Z*E ‘1 
‘Zf.0 ‘1’0 30 asop sfqoq B se pa.Ia~s!u!wpe S??M louaJalo.rdosI 
580~ IsaqD pas013 lDelu! IClp2+uouo~nt2 x!s u! uo!sn3u! a3utw 
-aluyu lolqos q3ea %ugnp pa]EadaJ uaql put! uoyw~s~uy~ 
-pe lolelos alo3aq pal3nJlsuo3 aJaM sahJn3 asuodsa.I-asop 
loua.taloIdosI woyanlma a.suodsaJ-asop IouaraloJdosI 
.laAal asop q3Ea 1~ lolelos 30 uo!sn3u! aDwuaiu!tw aql %upnp 
u#?r! pw uoy~~ls~uyp~ lolelos alo3aq apew alaM (spoyad 
AropeyaJ IqnyquaA pue I~.IIE JO saAJn3 asuodsal-asop 
loualaloldos! laql!a) sluawa.uweafl -Iale u!m g undaq st2~ 
uo!sn3u! a~uwaluyu aql pue uy 01 .IaAo palals!u!urpe alaM 
.~a~el u!m g un8aq SCM uo!sn3u! aaueualu!em aq, pue uyu 01 Jai\0 paJa]syrupe 
JJ~M sasop %u!peo7 ‘lolelos 30 suoye %u!yaolq-elaq aqi 30 aauapuadap uo!leJiuaauos aql k3yuenb 01 paw aJaM 
apeyso[q syIIouoIne Inoq)!M S%Oa ,sagJadoJd %U!yaOlq $JaUaJpe-elaq 30 hl)UapUadkyJ! (po!Jad i(JOlXgaJ aA!]aaaa 
.Itqns!JluaA pue [eye UO) lo[elos 30 slsa33a 111 adAl aql alnseaw 01 pasn aJaM apeysolq s!wouo~ne q]!M s%oa, 
O’E 7 P’S1 6’1 T 8’IZ 0’5 O’P s asoa 
O’Z z 2’6 6’0 z P’ll 0’1 O’Z P asoa 
6’0 +- 8’t S’O T P’P OP.0 08’0 t asoa 
P’O + P’I P’O + 9’1 01’0 oz.0 2 asoa 
I’0 + P’O 5’0 + 8’0 ZO’O PO’0 I asoa 
(9 = u) (9 = u) (4 Jad WW @i/w 
apevois *apevols asoa asueuayeti asoa %u!peoT 
s!mouo~ny ItlOql!M yownv qI!M 
(Jal!l/t?w) uo!leJ~uaxJo~ ewsqd 
s%oa ~1 u! uoywua~10~ eluseld Buglnsax pus lolelos 30 sasoa ‘1 alqsL 
107VIOS tt0 S3I~VNACI03VkQlVHd 
1611 ‘W 13 -IBLLVN 
bo61 I a61 Wv 
5 ‘ON ‘El ‘PA 33Vl 
1192 NATTEL ET AL. 
PHARMACODYNAMICS OF SOTALOL 
JACC Vol. 13, No. 5 
April 1989: 1 l!W-l 
0- - 0 CONTROL 
??-•DOSE 1 
A- - ADOSE 2 
20,-,_ A-ADOSE 3 
??- - ??DOSE 4 
1 2 5 10 20 50 100 200 500 
ISOPROTERENOL DOSE (mcg) 
Figure 1. Isoproterenol dose-response curves before and after a 
series of incremental loading and maintenance doses of sotalol in a 
representative experiment. As expected for a competitive beta- 
blocker, sotalol shifts the isoproterenol dose-response curve to the 
right. We quantified the beta-blocking action of sotalol by measuring 
the isoproterenol dose (the ED,,) required for 50% of maximal effect 
under control conditions (in this case about 5 pg), and then 
determining the degree of attenuation of the effect of this isoproter- 
enol dose by each dose of sotalol. See Table 1 for definition of doses 
1 tos. 
standard and there was complete baseline separation. The 
amplitude of each signal was compared with a calibration 
curve from a three-point (duplicate sample) standard curve 
performed on the same day. The mean coefficient of varia- 
tion was 3.3% and the lower limit of detection was 0.125 mgl 
liter. 
Solutions and chemicals. Isoproterenol hydrochloride 
was obtained from Sigma Chemical Inc. and administered in 
a mixture of isotonic saline solution and 0.1% ascorbic acid 
to prevent oxidation. Both d,l-sotalol and MJ 8181 (internal 
standard) were supplied by Bristol Myers Corp. Sotalol was 
administered in isotonic saline solution. 
Statistical methods. Group values are presented as the 
mean values ? SE. Comparisons between groups of data 
were performed by analysis of variance with a range test, 
and comparisons between two means only were performed 
by Student’s t test for either paired or unpaired samples (6). 
A two-tailed p value co.05 was taken to indicate statistical 
significance. 
Results 
Effects of sotalol. Sotalol produced a dose-related, paral- 
lel shift of the isoproterenol dose-response curve in the six 
autonomically intact dogs, as expected for a competitive 
beta-blocker (Fig. 1). As a result of its type III actions, 
sotalol caused a dose-related increase in atria1 and ventric- 
ular effective refractory period (Table 2). Significant changes 
in refractoriness occurred at doses higher than those re- 
quired for a statistically significant rightward shift in the 
isoproterenol dose-response curve (as indicated by the 
ED,,). 
Concentration dependence of beta-blocking and type III 
actions. Plasma concentrations of sotalol were slightly 
higher in the six dogs with autonomic blockade (Table l), but 
the differences in plasma concentrations were not statisti- 
cally significant at any dose level. Concentration-response 
analysis revealed major differences in the concentration 
dependence of the beta-blocking and type III actions of 
sotalol (Fig. 2). Half-maximal beta-blocking effects were 
seen at a mean concentration of 0.8 ? 0.3 mg/liter. This 
value was substantially lower than the concentrations re- 
quired for half-maximal effects on atria1 effective refractory 
period (6.9 2 1.2 mglliter, p < 0.01) or ventricular effective 
refractory period (6.8 + 2.8 mg/liter, p < 0.05). Sotalol 
produced larger changes in atria1 than in ventricular effective 
refractory period, and the difference between the magnitude 
of these effects was significant (p < 0.05) for the largest dose 
of sotalol. Sotalol’s effect on neither atria1 effective refrac- 
tory period nor ventricular effective refractory period was 
frequency dependent. 
Discussion 
Sotalol is a beta-adrenergic receptor antagonist with 
unique class III antiarrhythmic action (3). Its clinical use is 
increasing because of its unique profile of action and the 
limited availability of class III compounds. Because it has 
Table 2. Dose-Dependent Beta-Adrenergic Blocking and Type III Effects of Sotalol in 12 Dogs 
Control 
Group Dose I Dose 2 Dose 3 Dose 4 Dose 5 
Isoproterenol ED,,,* (kg) 2.8 ? 0.6 II.5 5 2.6t 17.0 ? 4.7t 39.2 ? 5.1$ 96.5 t 16.5$ 213.7 ? 37.8$ 
Atrial ERP (ms) 171 ? 14 171 ? 14 175 ? 12 185 ? IS 208 ? 1% 227 ? 23$ 
Ventricular ERP (ms) 181 t 16 181 2 16 183 + 15 194 ? 17 207 + 21$ 220 2 23$ 
*Isoproterenol ED,, = dose of isoproterenol required for 50% of maximal heart rate change, obtained from the isoproterenol dose-response curve; atrial, 
ventricular ERP = atria1 and ventricular effective refractory period, respectively, determined by the extrastimulus technique. tp < 0.05; Sp < 0.01 compared with 
corresponding control value. Isoproterenol EDSo was measured before and after various doses of sotalol in six autonomically intact dogs. Pure type III effects 
of sotalol as reflected by changes in atrial and ventricular effective refractory period (ERP) were evaluated in a separate set of six dogs with autonomic blockade 
as described in the text. The doses of sotalol used and the resulting plasma concentrations are shown in Table I. 
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Figure 2. Isoproterenol (ISO) concentration-response curves for the 
beta-adrenergic blocking effects (in six autonomically intact dogs), 
and for the class III actions (determined in six dogs with autonomic 
blockade) of sotalol on atria1 and ventricular refractoriness. Beta- 
blocking effects were seen at concentrations one order of magnitude 
less than those required for class III actions. For any given plasma 
concentration, sotalol increased atrial effective refractory period 
(ERP) more than ventricular effective refractory period (ERP). The 
difference between the magnitude of effects on the atrium and the 
ventricle was statistically significant (p < 0.05) at the highest dose of 
sotalol. 
two clinically relevant actions, beta-blocking and direct 
membrane (class III) effects, it is important to know the 
concentration ranges over which each action is expected to 
play a role. Pure beta-blockers such as metoprolol have been 
found to produce statistically significant (albeit modest) 
increases in QT interval and monophasic action potential 
duration (7). It is therefore necessary to eliminate the effect 
of beta-receptor-mediated changes in repolarization to ana- 
lyze the concentration dependence of pure type III actions of 
sotalol. We achieved this state in our dogs by first producing 
chemical autonomic blockade and then comparing refractory 
periods before and after sotalol in the continuous absence of 
beta-mediated sympathetic effects. 
Comparison with other studies of sotalol’s actions. We 
found a major disparity between the sotalol concentrations 
producing substantial beta-blockade and those required to 
increase atria1 and ventricular refractory periods in dogs by 
class III actions. This disparity is consistent with in vitro 
data (2,8) suggesting that sotalol blocks the effects of beta- 
agonists at concentrations much lower than those increasing 
action potential duration. Clinical studies (4,9) have also 
indicated that significant QT, prolongation by sotalol re- 
quires concentrations substantially higher than those pre- 
venting exercise-induced tachycardia. 
We found that half-maximal beta-blockade occurred at a 
sotalol concentration of 0.8 + 0.3 mglliter. This finding is 
similar to the results of Wang et al. (4), who observed 50% of 
maximal attenuation of exercise-induced tachycardia in pa- 
tients at a concentration of 0.8 mgiliter. On the other hand, 
we observed half-maximal increases in atria1 and ventricular 
refractory period at sotalol plasma concentrations of 6.9 and 
6.8 mg/liter, respectively. Maximal increases in atria1 and 
ventricular effective refractory period averaged 32.2 ? 4.0% 
and 20.8 t 3.3%, respectively, at a cumulative sotalol 
loading dose of 8.84 mg/kg. These values are in the range of 
values reported by other investigators, who found that 4.5 
mgikg of sotalol increased ventricular effective refractory 
period in normal tissues by 14% (10) and 8 mgikg increased 
ventricular effective refractory period by 15 to 20% (11) in 
conscious dogs. These results are also in keeping with the 
degree of action potential duration prolongation in ventric- 
ular muscle produced by a similar range of concentrations in 
vitro (1.2,8,12). 
Our study differs from previous in vivo pharmacodynamic 
e\laluations of sotalol’s beta-blocking and type III actions 
(4,9) in several important ways. We evaluated pure class III 
actions of sotalol by eliminating autonomic influences 
through chemical autonomic blockade. Our analysis of beta- 
blocking action was based on isoproterenol dose-response 
curves, a more precise measure than the attenuation of 
exercise-induced tachycardia previously used (4,9). Because 
we were working with experimental animals, we were able to 
study the effects of five stable and comparable sotalol dose 
levels in all animals. Our work therefore complements 
previous clinical studies (4,9) and confirms the clear differ- 
ences between sotalol doses needed for beta-blocking and 
class III actions. 
Clinical relevance. There is considerable variation in the 
magnitude of type III action reported for sotalol in patients. 
Several studies (13-16) have reported increases of <IO% in 
corrected QT (QT,) intervals with mean sotalol doses rang- 
ing from 300 to 640 mg daily. Others (17-19) have reported 
mean QT, increases between 10% and 13.4% at mean sotalol 
plasma concentrations of 1.7 to 3 mgiliter. Thus, whereas 
changes in repolarization are produced by sotalol in humans 
at slightly lower concentrations than is the case in dogs, type 
III actions require clearly larger concentrations than those 
needed to cause beta-blockade. Type III effects are rela- 
tively minor at the commonly used dose range of 160 to 320 
mg daily, which produces mean plasma sotalol concentra- 
tions in the range of 0.4 to 0.8 mgiliter (4). 
The potential clinical role of sotalol’s type III actions 
needs further appraisal. It is possible that selective action 
potential prolongation in diseased tissues, as shown previ- 
ously for dogs with myocardial infarction (101, plays a role in 
sotalol’s efficacy in the treatment of ventricular arrhythmias 
(15.20,21). even at concentrations with modest class III 
actions on normal tissues. We found that sotalol produced 
significantly greater type III actions in the atrium compared 
with the ventricle. This result is in agreement with previous 
clinical observations (19,22) and suggests that supraventric- 
ular arrhythmias may be controlled by lower sotalol concen- 
trations than are necessary for ventricular arrhythmias. 
Although the type 111 actions of sotalol would be expected 
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to prevent lethal ventricular tachyarrhythmias, the drug is 
no more effective than other beta-blockers in preventing 
sudden death after myocardial infarction (23); however, the 
only long-term study of sotalol after infarction (24) used 
doses that would be inadequate to produce important 
changes in repolarization. Other trials (25) found no differ- 
ences in the effects on ventricular refractoriness and tachy- 
arrhythmias of sotalol and metoprolol, again at sotalol doses 
(160 to 320 mg/day) that our results indicate are insufficient 
to produce substantial class III effects. Consideration of the 
concentration-dependence of sotalol’s type III action is 
important in analyzing the results of such clinical trials. 
Conclusions. We have found that sotalol’s pure class III 
actions require much larger concentrations than those pro- 
ducing beta-blockade. These pharmacodynamic differences 
must be considered in further studies of the mechanisms of 
sotalol’s antiarrhythmic actions and their clinical impor- 
tance. 
We thank Lena Barbeau and Lise de Repentigny for typing the manuscript 
and Bristol Myers Corp. for supplying d,l-sotalol and internal standard. 
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